ADCs overtake mAbs in AACR’s first-in-human abstracts

Antibody-drug conjugates outnumber traditional mAbs in the first-in-human studies presented at AACR this year, which could be a sign that the next-generation antibody design is reaching maturity, or at least moving beyond new modality status.

Among the 25 abstracts presented at the American Association for Cancer Research (AACR) annual meeting this week that describe initial data from first-in-human studies, or describe ongoing first-in-human studies from which data have yet to be disclosed, eight cover antibody-drug conjugates (ADC) while five describe traditional mAb therapeutics. ...